Vaishali Pharma adjusts allotment consideration based on valuation report
Vaishali Pharma Ltd will receive ₹2,15,258 from Kesar Pharma Ltd to align preferential allotment consideration with a registered valuer's report. The adjustment addresses a ₹0.10 per share difference on 21,52,575 shares acquired.

*this image is generated using AI for illustrative purposes only.
Vaishali Pharma Ltd will receive ₹2,15,258 in cash from Kesar Pharma Ltd to align the consideration for a preferential allotment with a registered valuer's report. The adjustment addresses a discrepancy of ₹0.10 per share on 21,52,575 equity shares of Kesar Pharma Ltd acquired by the company. This ensures the transaction complies with the valuation determined by the Registered Valuer and applicable regulatory requirements.
The company's members had approved the issuance of up to 61,23,000 equity shares on a preferential basis to Kesar Pharma Ltd through a postal ballot on March 15, 2026. The approval was initially based on acquiring 21,52,575 equity shares of Kesar Pharma Ltd at a value of ₹56.89 per equity share. However, the valuation report later determined the value at ₹56.79 per equity share, creating the differential amount.
The following table outlines the financial details of the adjustment:
| Particulars | Details |
|---|---|
| Total shares of Kesar Pharma Ltd acquired | 21,52,575 |
| Initial valuation per share (₹) | 56.89 |
| Registered Valuer's price per share (₹) | 56.79 |
| Difference per share (₹) | 0.10 |
| Aggregate differential amount (₹) | 2,15,258 |
The aggregate differential amount of ₹2,15,258, calculated at ₹0.10 per share on the total shares acquired, will be received in cash from Kesar Pharma Ltd. Consequently, the consideration for the transaction stands adjusted to the extent of this amount. This disclosure was made pursuant to an observation received from the National Stock Exchange of India Limited in connection with the company's application for in-principle approval.
Historical Stock Returns for Vaishali Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.04% | +5.71% | +10.48% | -14.33% | -38.79% | +94.62% |
How will this cash adjustment impact Vaishali Pharma's working capital or liquidity position in the upcoming quarter?
Does the resolution of this valuation discrepancy expedite the National Stock Exchange's approval for the preferential allotment?
What strategic benefits does Vaishali Pharma expect to gain from acquiring equity shares in Kesar Pharma Ltd?



























